Similar efficacy of thalidomide- and bortezomib-based regimens for first relapse of multiple myeloma
Identifikátory výsledku
Kód výsledku v IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14110%2F11%3A00052147" target="_blank" >RIV/00216224:14110/11:00052147 - isvavai.cz</a>
Nalezeny alternativní kódy
RIV/00216208:11110/11:11276 RIV/65269705:_____/11:#0001311 RIV/00064190:_____/11:#0000235 RIV/00064165:_____/11:11276 RIV/00064173:_____/11:#0000382
Výsledek na webu
<a href="http://dx.doi.org/10.1007/s00277-011-1206-3" target="_blank" >http://dx.doi.org/10.1007/s00277-011-1206-3</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1007/s00277-011-1206-3" target="_blank" >10.1007/s00277-011-1206-3</a>
Alternativní jazyky
Jazyk výsledku
angličtina
Název v původním jazyce
Similar efficacy of thalidomide- and bortezomib-based regimens for first relapse of multiple myeloma
Popis výsledku v původním jazyce
Many regimens containing novel drugs have been developed for multiple myeloma (MM). It is not yet clear whether some of the novel agents are better than others. In a retrospective study, we have analyzed the outcomes of patients with first relapse of MMtreated with thalidomide-based (T) regimens (n=105) or bortezomib-based (B) regimens (n=106). Both T and B groups were comparable regarding basic clinical parameters and first-line therapies. Combination of thalidomide with an alkylating drug (A) and dexamethasone (D) was used in 91 cases, T with D in five cases, and T alone in nine cases. A combination of bortezomib with A and D was used in 58 patients, B with D or A in 40 patients, and B alone in eight patients. In the T group, ORR was 51%, median TTPfrom the start of treatment for relapse of 13.1 months, and median OS of 30.4 months. In the B group, ORR was 50% with median TTP of 16.7 months and median OS of 37.2 months. No significant differences in ORR (p=0.774), TTP (p=0.207), or
Název v anglickém jazyce
Similar efficacy of thalidomide- and bortezomib-based regimens for first relapse of multiple myeloma
Popis výsledku anglicky
Many regimens containing novel drugs have been developed for multiple myeloma (MM). It is not yet clear whether some of the novel agents are better than others. In a retrospective study, we have analyzed the outcomes of patients with first relapse of MMtreated with thalidomide-based (T) regimens (n=105) or bortezomib-based (B) regimens (n=106). Both T and B groups were comparable regarding basic clinical parameters and first-line therapies. Combination of thalidomide with an alkylating drug (A) and dexamethasone (D) was used in 91 cases, T with D in five cases, and T alone in nine cases. A combination of bortezomib with A and D was used in 58 patients, B with D or A in 40 patients, and B alone in eight patients. In the T group, ORR was 51%, median TTPfrom the start of treatment for relapse of 13.1 months, and median OS of 30.4 months. In the B group, ORR was 50% with median TTP of 16.7 months and median OS of 37.2 months. No significant differences in ORR (p=0.774), TTP (p=0.207), or
Klasifikace
Druh
J<sub>x</sub> - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)
CEP obor
FD - Onkologie a hematologie
OECD FORD obor
—
Návaznosti výsledku
Projekt
—
Návaznosti
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Ostatní
Rok uplatnění
2011
Kód důvěrnosti údajů
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Údaje specifické pro druh výsledku
Název periodika
Annals of hematology
ISSN
0939-5555
e-ISSN
—
Svazek periodika
90
Číslo periodika v rámci svazku
12
Stát vydavatele periodika
DE - Spolková republika Německo
Počet stran výsledku
7
Strana od-do
1441-1447
Kód UT WoS článku
000296730700008
EID výsledku v databázi Scopus
—